Home » Spectranetics Submits 510(k) Application for In-Stent Restenosis in the Legs
Spectranetics Submits 510(k) Application for In-Stent Restenosis in the Legs
Spectranetics Corporation announced that it has filed a 510(k) application with the Food and Drug Administration seeking clearance for the treatment of in-stent restenosis in the legs with its commercially available peripheral atherectomy products.
TradingMarkets
TradingMarkets
Upcoming Events
-
07May
-
14May
-
30May